Form 4: Rhythm Pharmaceuticals Executive Yann Mazabraud Reports Stock Transactions

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, reports the vesting and disposal of restricted stock units.

Summary

• Yann Mazabraud, an executive at Rhythm Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions on April 14 and 15, 2025.
• These transactions involve the vesting and disposal of restricted stock units (RSUs) that convert into common stock.
• On April 14, 2025, 10,375 RSUs vested and were disposed of.
• On April 15, 2025, 11,405 RSUs vested and were disposed of.
• The reporting person still owns 7,500 RSUs.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't indicate any specific positive or negative sentiment about the company's performance.

Industry Context

Executive stock transactions are a normal part of corporate governance and compensation practices in publicly traded companies. They provide insights into executive sentiment but are also driven by vesting schedules and personal financial planning.

Comparison to Industry Standards

• Executive compensation packages, including restricted stock units, are common across the pharmaceutical industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize RSUs as part of their executive compensation plans.
• The vesting schedules and amounts of RSUs can vary widely based on company size, performance, and individual executive roles.

Stakeholder Impact

• The transactions have a minor dilutive effect on existing shareholders due to the issuance of new shares upon RSU vesting.
• The transactions reflect part of the executive's compensation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Rhythm Pharmaceuticals, RYTM, Yann Mazabraud, Restricted Stock Units, Stock Transactions, Executive Compensation